Health
CARsgen Appoints Dr. Hua Jiang as Executive Director
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...
2022-08-02 20:50
2146
Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...
2022-08-02 20:39
1545
Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial Production
* GMP commercial manufacturing license authorized by the National Drug Regulatory Authority, demonstrating Chime Biologics' capabilities in large scale commercial production * Only 18 months to help LEPU Biopharma to obtain the approval of Puyouheng ™ ina new drug application demonstrating "...
2022-08-02 20:15
1491
China Life Insurance Company Limited - Change of President
BEIJING, Aug. 2, 2022 /PRNewswire/ -- China Life Insurance Company Limited (the "Company") (NYSE: LFC; SSE: 601628; HKSE: 2628) announced today that due to the adjustment of work arrangements, Mr. Su Hengxuan tendered his resignation as the President, an Executive Director and a member of the Str...
2022-08-02 18:57
2382
NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent
ADELAIDE, Australia, Aug. 2, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix GalienUSA Award for Best Pharmaceutical A...
2022-08-02 13:00
1559
OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology
2022 is set to be a milestone year for OriCell who has been focusing on the
field of cancer immunotherapy for more than seven years and is fully committed
to becoming an innovative global drug developer.
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- OriCell Therapeutics
2022-08-01 22:00
2323
"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August
CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...
2022-08-01 22:00
1950
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...
2022-08-01 21:00
2255
Yunji's Technology-empowered Private Label SUYE Celebrates Its 12th Anniversary
HANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced the celebration of its private-label skin care brand SUYE's 12th anniversary. SUYE generated over21 million RMB sales of its hig...
2022-08-01 21:00
2701
New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...
2022-08-01 21:00
1853
Bon Natural Life Limited Announces Record First Half-Year Revenue and Net Income
1H-2022 Revenue increases by 17.0% to $13.7 million XI'AN, China, Aug. 1, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its half-year...
2022-08-01 20:30
2656
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer
Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...
2022-08-01 20:00
1919
Meihua International Medical Technologies Co., Ltd. Reports 2021 Financial Year Results
YANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today reported its financial res...
2022-08-01 19:00
2528
Eccogene Announces US IND Approval for THRβ agonist ECC4703
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...
2022-08-01 15:00
1528
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:22
1609
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:17
1570
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...
2022-07-29 20:00
2946
HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial
SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current ...
2022-07-29 19:00
2066
ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China
GUANGZHOU, China, July 29, 2022 /PRNewswire/ -- The inaugural ZAODX World Conference on Early Detection of Cancer ("the Conference") was successfully held at the Chimelong International Conference Center inGuangzhou from July 15-17, 2022. In attendance were founders and representatives from over ...
2022-07-29 15:35
1509
MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL
* Mayne Pharma enters into strategic agreement with GoodRx * GoodRx and Mayne Pharma to collaborate and deliver an enhanced NEXTSTELLIS® direct-to-consumer (DTC) program ADELAIDE, Australia, July 29, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce a new strat...
2022-07-29 13:00
1596
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 292 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Most Read
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10151
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7509
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6226
